---
title: "New research challenges established thinking on rare genetic disorder's inflammation cause"
url: https://noti.group/new-research-challenges-established-thinking-on-rare-genetic-disorder/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-11-18T12:33:09.000Z
updated: 2026-11-18T18:01:03.133Z
id: 0d3b09ae-922d-4e69-b569-8275b374a555
source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/11/261117035052.htm"
attribution: "Link to https://noti.group/new-research-challenges-established-thinking-on-rare-genetic-disorder/ and name Noti Group when you quote or summarize this story."
---

# New research challenges established thinking on rare genetic disorder's inflammation cause

A recent study reveals that natural killer cells malfunction in people with mevalonate kinase deficiency (MKD), leading to excessive inflammation.

Scientists have long believed they understood the root cause of a rare genetic disorder's associated inflammation. However, new research at the Garvan Institute of Medical Research has uncovered evidence challenging this established thinking and potentially paving the way for a new treatment.

The condition in question is mevalonate kinase deficiency (MKD), which can trigger severe inflammatory episodes that are sometimes life-threatening. A recent study published in Immunity reveals an underappreciated issue involving natural killer cells, immune cells typically responsible for eliminating infected cells from the body.

Researchers have found that these natural killer cells malfunction in people with MKD, leading to excessive inflammation when infections occur. This discovery also hints at a possible treatment using existing medications known as JAK inhibitors, which could be particularly beneficial for patients who do not respond to current therapies.

The study's senior author, Professor Mike Rogers of the Garvan Institute, suggests that this research has identified a new target for treating MKD and sets the stage for further clinical studies exploring the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD.

Researchers have been trying to understand a rare immune disorder known as MKD for decades, but despite some progress, many patients still don't respond well to existing treatments. The condition affects hundreds of children and adults worldwide, causing recurring attacks of high fever, skin rashes, joint pain, and inflammation in the abdomen that can be potentially fatal.

For years, scientists have focused on macrophages, immune cells responsible for coordinating the body's inflammatory response. However, this approach has limitations, as nearly half of patients don't respond adequately to treatments designed to block an inflammatory signal released by these cells. This suggests that there may be more to MKD than just macrophage dysfunction.

To shed new light on the condition, researchers at the Garvan Institute examined blood samples from people with MKD and developed preclinical models of the disorder. Their goal was to identify any gaps in the current understanding of the disease, which could lead to improved treatment options for patients who don't respond well to existing therapies.

The team's experiments revealed a critical defect in natural killer cells, which play a vital role in the body's early defenses against viral infections. In people with MKD, these cells fail to mature properly and struggle to destroy infected cells before an infection can spread.

The immune system's response to infection is a complex process that involves multiple cell types working together to eliminate threats. However, when natural killer cells fail to perform their role, they can trigger a cascade of events that leads to widespread inflammation.

In people with MKD, the failure of natural killer cells to kill infected cells results in an overactive immune response. This is caused by the release of large amounts of inflammatory signaling molecules, which activate other parts of the immune system and lead to fever and inflammation.

According to Professor Rogers, the misfiring of these immune cells has significant consequences for patients with MKD. We found that these immune cells are essentially malfunctioning, he explains.

The findings suggest that natural killer cell dysfunction is a key factor in driving MKD. This challenges previous research on the disease, which has focused on macrophage activity as the primary cause of the condition.

Dr. Munoz emphasizes the significance of the new understanding of MKD, saying In MKD, the main problem lies with NK cells and not with macrophages.

The researchers at Garvan collaborated with Professor Mariapia Degli-Esposti and her team at Monash University to investigate how a cellular defect contributes to MKD.

Using preclinical models, they established a link between malfunctioning natural killer cells and the severe symptoms of MKD. The experiments showed that when the immune system fails to clear a viral infection, it triggers an inflammatory response that causes extensive damage to organs.

This finding helps explain why a disorder involving defective immune defenses can also lead to episodes of extreme inflammation. It highlights the complex relationship between immune dysfunction and organ damage in MKD patients.

The discovery has already guided an experimental treatment approach for a severely affected infant. Working with doctors at the Royal Children's Hospital, the researchers explored whether baricitinib could reduce excessive inflammatory signaling associated with MKD.

Baricitinib is a JAK inhibitor that interferes with immune system signaling pathways, including those involved in responses to interferon gamma. It is used to treat other immune-related conditions like rheumatoid arthritis and eczema.

The findings from a single patient's case offer promising early evidence that targeting interferon gamma activity can lead to improvement in symptoms.

Researchers are now considering conducting further clinical studies involving JAK inhibitors and other medications that block interferon gamma activity in patients with MKD who have not responded to standard treatments.

This breakthrough has significant implications extending beyond the treatment of MKD itself, as it may shed light on related genetic disorders involving the same metabolic pathway.

According to early research, these "prenylopathies share a similar underlying problem, where natural killer cells fail to function properly and instead produce excessive inflammatory signals.

Research on a rare disease has uncovered a previously unknown vulnerability in the immune system, where natural killer cells malfunction and produce excessive inflammatory signals.

This underlying issue is thought to be common among various prenylopathies" that are currently being studied by scientists, who believe that a single treatment or intervention could potentially address these related conditions.

---
Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/11/261117035052.htm)  
Published by Noti Group: https://noti.group/new-research-challenges-established-thinking-on-rare-genetic-disorder/
